Rebecca Anne Miksad

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8710156/publications.pdf

Version: 2024-02-01

43 papers

4,505 citations

279798 23 h-index 254184 43 g-index

44 all docs 44 docs citations

times ranked

44

6559 citing authors

#	Article	IF	CITATIONS
1	Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approachâ€"The ALBI Grade. Journal of Clinical Oncology, 2015, 33, 550-558.	1.6	1,810
2	Efficacy, Safety, and Potential Biomarkers of Sunitinib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study. Journal of Clinical Oncology, 2009, 27, 3027-3035.	1.6	467
3	Prospective Study of Bevacizumab Plus Temozolomide in Patients With Advanced Neuroendocrine Tumors. Journal of Clinical Oncology, 2012, 30, 2963-2968.	1.6	257
4	Stereotactic Body Radiotherapy and Gemcitabine for Locally Advanced Pancreatic Cancer. International Journal of Radiation Oncology Biology Physics, 2010, 78, 735-742.	0.8	215
5	Induction Gemcitabine and Stereotactic Body Radiotherapy for Locally Advanced Nonmetastatic Pancreas Cancer. International Journal of Radiation Oncology Biology Physics, 2011, 81, e615-e622.	0.8	207
6	Phase 1/2 study of everolimus in advanced hepatocellular carcinoma. Cancer, 2011, 117, 5094-5102.	4.1	177
7	Quality of Life Implications of Bisphosphonate-Associated Osteonecrosis of the Jaw. Oncologist, 2011, 16, 121-132.	3.7	133
8	Identification of prognostic biomarkers in hepatitis B virus-related hepatocellular carcinoma and stratification by integrative multi-omics analysis. Journal of Hepatology, 2014, 61, 840-849.	3.7	131
9	Realâ€world progression, treatment, and survival outcomes during rapid adoption of immunotherapy for advanced non–small cell lung cancer. Cancer, 2019, 125, 4019-4032.	4.1	115
10	Generating Real-World Tumor Burden Endpoints from Electronic Health Record Data: Comparison of RECIST, Radiology-Anchored, and Clinician-Anchored Approaches for Abstracting Real-World Progression in Non-Small Cell Lung Cancer. Advances in Therapy, 2019, 36, 2122-2136.	2.9	111
11	Progression-free survival as a surrogate endpoint in advanced breast cancer. International Journal of Technology Assessment in Health Care, 2008, 24, 371-383.	0.5	82
12	Does a Statistically Significant Survival Benefit of Erlotinib Plus Gemcitabine for Advanced Pancreatic Cancer Translate Into Clinical Significance and Value?. Journal of Clinical Oncology, 2007, 25, 4506-4507.	1.6	75
13	Characterizing the Feasibility and Performance of Real-World Tumor Progression End Points and Their Association With Overall Survival in a Large Advanced Non–Small-Cell Lung Cancer Data Set. JCO Clinical Cancer Informatics, 2019, 3, 1-13.	2.1	69
14	Safety of Bevacizumab in Patients with Advanced Cancer: A Meta-Analysis of Randomized Controlled Trials. Oncologist, 2010, 15, 1179-1191.	3.7	63
15	Real-World Outcomes of Patients with Metastatic Non-Small Cell Lung Cancer Treated with Programmed Cell Death Protein 1 Inhibitors in the Year Following U.S. Regulatory Approval. Oncologist, 2019, 24, 648-656.	3.7	60
16	Methods for Measuring Temporary Health States for Cost-Utility Analyses. Pharmacoeconomics, 2009, 27, 713-723.	3.3	48
17	Prostate Cancer in a Transgender Woman 41 Years After Initiation of Feminization. JAMA - Journal of the American Medical Association, 2006, 296, 2312.	7.4	46
18	Phase I and Biomarker Study of the Wnt Pathway Modulator DKN-01 in Combination with Gemcitabine/Cisplatin in Advanced Biliary Tract Cancer. Clinical Cancer Research, 2020, 26, 6158-6167.	7.0	37

#	Article	IF	Citations
19	Comparative cost-effectiveness of strategies to prevent postoperative clinical recurrence of Crohnʽs disease. Inflammatory Bowel Diseases, 2012, 18, 1608-1616.	1.9	36
20	From Treatment to Prevention: The Interplay Between HIV/AIDS Treatment Availability and HIV/AIDS Prevention Programming in Khayelitsha, South Africa. Journal of Urban Health, 2005, 82, 498-509.	3.6	35
21	Exploratory Analysis of Early Toxicity of Sunitinib in Advanced Hepatocellular Carcinoma Patients: Kinetics and Potential Biomarker Value. Clinical Cancer Research, 2011, 17, 918-927.	7.0	29
22	Treatment of Cancer Pain with Noninvasive Brain Stimulation. Journal of Pain and Symptom Management, 2007, 34, 342-345.	1.2	28
23	A comparison of surgical outcomes for noncirrhotic and cirrhotic hepatocellular carcinoma patients in a Western institution. Surgery, 2013, 154, 545-555.	1.9	27
24	Real-World Dosing Patterns and Outcomes of Patients With Metastatic Pancreatic Cancer Treated With a Liposomal Irinotecan Regimen in the United States. Pancreas, 2020, 49, 193-200.	1.1	26
25	Small But Mighty: The Use of Realâ€World Evidence to Inform Precision Medicine. Clinical Pharmacology and Therapeutics, 2019, 106, 87-90.	4.7	24
26	Determinants and outcomes of adherence to recommendations from a multidisciplinary tumour conference for hepatocellular carcinoma. Hpb, 2014, 16, 1009-1015.	0.3	22
27	Interpreting Trial Results in Light of Conflicting Evidence: A Bayesian Analysis of Adjuvant Chemotherapy for Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2009, 27, 2245-2252.	1.6	19
28	Association of Programmed Cell Death Ligand 1 Expression Status With Receipt of Immune Checkpoint Inhibitors in Patients With Advanced Non–Small Cell Lung Cancer. JAMA Network Open, 2020, 3, e207205.	5.9	19
29	Hepatic Hydrothorax Associated With Vitamin A Toxicity. Journal of Clinical Gastroenterology, 2002, 34, 275-279.	2.2	18
30	Cost-effectiveness of primarily human papillomavirus–based cervical cancer screening in settings with currently established Pap screening: A systematic review commissioned by the German Federal Ministry of Health. International Journal of Technology Assessment in Health Care, 2008, 24, 184-192.	0.5	18
31	DETECTION OF PROSTATE CANCER FOLLOWING GENDER REASSIGNMENT. BJU International, 2008, 101, 259-259.	2.5	17
32	Real-World Outcomes for Advanced Non-Small Cell Lung Cancer Patients Treated With a PD-L1 Inhibitor Beyond Progression. Clinical Lung Cancer, 2020, 21, 389-394.e3.	2.6	14
33	Emulating Control Arms for Cancer Clinical Trials Using External Cohorts Created From Electronic Health Recordâ€Derived Realâ€World Data. Clinical Pharmacology and Therapeutics, 2022, 111, 168-178.	4.7	14
34	What is the role of adjuvant therapy after liver transplantation for hepatocellular carcinoma?. Liver Transplantation, 2011, 17, S147-S158.	2.4	13
35	Measuring the Quality-of-Life Effects of Diagnostic and Screening Tests. Journal of the American College of Radiology, 2009, 6, 567-575.	1.8	10
36	Impact of the COVID-19 Pandemic on Treatment Patterns for Patients With Metastatic Solid Cancer in the United States. Journal of the National Cancer Institute, 2022, 114, 571-578.	6.3	8

#	Article	IF	CITATIONS
37	Real-world association of HER2/ <i>ERBB2</i> concordance with trastuzumab clinical benefit in advanced esophagogastric cancer. Future Oncology, 2021, 17, 4101-4114.	2.4	7
38	Analysis of a Real-World Progression Variable and Related Endpoints for Patients with Five Different Cancer Types. Advances in Therapy, 2022, 39, 2831-2849.	2.9	5
39	Earlyâ€onset pancreatic cancer research: Making sense of confounding and bias. Cancer, 2021, 127, 3505-3507.	4.1	4
40	Imbalance and Gait Disturbance from Tyrosine Kinase Inhibition in Hepatocellular Cancer. Journal of Gastrointestinal Cancer, 2009, 40, 119-122.	1.3	3
41	When a Decision Must Be Made: Role of Computer Modeling in Clinical Cancer Research. Journal of Clinical Oncology, 2011, 29, 4602-4604.	1.6	2
42	Priming of Sorafenib Prior to Radiofrequency Ablation Does Not Increase Treatment Effect in Hepatocellular Carcinoma. Digestive Diseases and Sciences, 2021, , 1.	2.3	2
43	Disparities in cardiovascular disease mortality after breast cancer treatment: Methodological considerations using realâ€world data. Cancer, 2022, 128, 647-650.	4.1	2